Cardiovascular
![PC-PH-104646.png](/ph/sites/default/files/styles/bi_gds_card_style/public/2023-09/PC-PH-104646.png)
03:57
Boehringer Ingelheim’s Telmisartan is the ONLY ARB that is INDICATED* to reduce both CV morbidity and mortality for high-risk patients
![thumb.png](/ph/sites/default/files/styles/bi_gds_card_style/public/2023-09/thumb.png)
01:02
Telmisartan as initial dose for hypertension
![thumb_0.png](/ph/sites/default/files/styles/bi_gds_card_style/public/2023-09/thumb_0.png)
02:19
Cost Effectiveness – Price Comparison of Telmisartan (Micardis®) & Telmisartan + Amlodipine besilate (Twynsta®)
![second.jpg](/ph/sites/default/files/styles/bi_gds_card_style/public/2023-09/second.jpg)
04:16
Start with Boehringer Ingelheim’s Telmisartan in mild to moderate hypertensive patients
![three.jpg](/ph/sites/default/files/styles/bi_gds_card_style/public/2023-09/three.jpg)
03:37
Boehringer Ingelheim’s Telmisartan provides renal benefits to high-risk* hypertensive patients
![four.jpg](/ph/sites/default/files/styles/bi_gds_card_style/public/2023-09/four.jpg)
02:58